Grant: Discovery Grants Program - Individual
University of Alberta
$55,000.00
Molecular mechanism and regulation of cellular cholesterol homeostasis-ABC transporters and PCSK9
EF 2024-25
Résumé
Cholesterol is an essential component of mammalian cell membranes and has pleiotropic biological functions. However, excess cholesterol is cytotoxic. Cellular cholesterol homeostasis is tightly regulated by uptake, de novo synthesis, metabolism and efflux. After decades of research, many unknowns remain about how cells regulate cholesterol homeostasis. For example, PCSK9 regulates cholesterol metabolism via promoting LDLR degradation, and ATP-binding cassette transporter G1 (ABCG1) mediates cholesterol efflux. However, detailed underlying mechanisms remain elusive.
Objectives. The long-term objective of this program is to obtain a better fundamental understanding of molecular mechanisms by which cholesterol homeostasis is regulated. Short-term objectives are to determine how PCSK9 promotes LDLR degradation and how ABCG1 mediates cholesterol efflux.
Hypothesis and methods. Our preliminary data showed that PCSK9-promoted LDLR degradation required clathrin- and caveolae-mediated endocytosis in a cell type-dependent manner and that ABCG1 and caveolin 1 (CAV1) were present in lipid rafts. Thus, we hypothesize that PCSK9 requires cofactors and clathrin- or caveolae-mediated endocytosis to promote LDLR degradation in a cell type-dependent manner. We also hypothesize that palmitoylation of ABCG1 mediated by specific palmitoyltransferases/DHHCs directs ABCG1 to cholesterol-rich lipid rafts, where ABCG1 interacts with CAV1. ATP hydrolysis in ABCG1 reduces cholesterol binding to CAV1, making cholesterol a favorable source for efflux. Thus, we will determine
1) the role of CAV1 and clathrin heavy chain (CLTC) in PCSK9-promoted LDLR degradation in primary hepatocytes. CAV1 and CLTC are an essential component of caveolae- and clathrin-mediated endocytosis, respectively. Their expression will be knocked down by siRNA. Cells will be incubated with or without PCSK9, followed by qRT-PCR and Western Blot to detect expression of targets (e.g. LDLR, CAV1, CLTC).
2) cofactors involved in PCSK9's action on LDLR. PCSK9-TurboID will be used to biotinylate proteins in proximity to PCSK9, which will be pulled down and submitted for proteomics to identify potential cofactors.
3) palmitoylation and lipid raft localization of ABCG1, and cholesterol binding to CAV1. Cells will be treated with a palmitoylation inhibitor, followed by a click reaction to detect ABCG1 palmitoylation. Lipid raft localization and cholesterol binding will be examined using Lubrol WX extraction and photoreactive cholesterol, respectively.
4) DHHCs involved in ABCG1 palmitoylation. Knockdown and overexpression will be used to determine which of the 23 DHHCs are involved in ABCG1 palmitoylation.
Impact. This research will provide novel information about how cells regulate cholesterol homeostasis. Further, the research will be conducted in a leading-edge laboratory, providing students with elite training in a broad range of expertise and techniques in biochemistry, molecular and cell biology.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2024-06088
Name nom
Zhang, Dawei
Department département
Pediatrics
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
55000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5405
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Lipids
Research subject fr
Lipides
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Molecular mechanism and regulation of cellular cholesterol homeostasis-ABC transporters and PCSK9
Keywords
cellular cholesterol homeostasis; cholesterol uptake and efflux; atp-binding cassette transporter; proprotein convertase subtilisin/kexin type 9; low density lipoprotein receptor; cell culture; palmitoylation; immunoprecipitation and western blot; real-time quantitative reverse transcription pcr; endocytosis
Application summary
Cholesterol is an essential component of mammalian cell membranes and has pleiotropic biological functions. However, excess cholesterol is cytotoxic. Cellular cholesterol homeostasis is tightly regulated by uptake, de novo synthesis, metabolism and efflux. After decades of research, many unknowns remain about how cells regulate cholesterol homeostasis. For example, PCSK9 regulates cholesterol metabolism via promoting LDLR degradation, and ATP-binding cassette transporter G1 (ABCG1) mediates cholesterol efflux. However, detailed underlying mechanisms remain elusive.
Objectives. The long-term objective of this program is to obtain a better fundamental understanding of molecular mechanisms by which cholesterol homeostasis is regulated. Short-term objectives are to determine how PCSK9 promotes LDLR degradation and how ABCG1 mediates cholesterol efflux.
Hypothesis and methods. Our preliminary data showed that PCSK9-promoted LDLR degradation required clathrin- and caveolae-mediated endocytosis in a cell type-dependent manner and that ABCG1 and caveolin 1 (CAV1) were present in lipid rafts. Thus, we hypothesize that PCSK9 requires cofactors and clathrin- or caveolae-mediated endocytosis to promote LDLR degradation in a cell type-dependent manner. We also hypothesize that palmitoylation of ABCG1 mediated by specific palmitoyltransferases/DHHCs directs ABCG1 to cholesterol-rich lipid rafts, where ABCG1 interacts with CAV1. ATP hydrolysis in ABCG1 reduces cholesterol binding to CAV1, making cholesterol a favorable source for efflux. Thus, we will determine
1) the role of CAV1 and clathrin heavy chain (CLTC) in PCSK9-promoted LDLR degradation in primary hepatocytes. CAV1 and CLTC are an essential component of caveolae- and clathrin-mediated endocytosis, respectively. Their expression will be knocked down by siRNA. Cells will be incubated with or without PCSK9, followed by qRT-PCR and Western Blot to detect expression of targets (e.g. LDLR, CAV1, CLTC).
2) cofactors involved in PCSK9's action on LDLR. PCSK9-TurboID will be used to biotinylate proteins in proximity to PCSK9, which will be pulled down and submitted for proteomics to identify potential cofactors.
3) palmitoylation and lipid raft localization of ABCG1, and cholesterol binding to CAV1. Cells will be treated with a palmitoylation inhibitor, followed by a click reaction to detect ABCG1 palmitoylation. Lipid raft localization and cholesterol binding will be examined using Lubrol WX extraction and photoreactive cholesterol, respectively.
4) DHHCs involved in ABCG1 palmitoylation. Knockdown and overexpression will be used to determine which of the 23 DHHCs are involved in ABCG1 palmitoylation.
Impact. This research will provide novel information about how cells regulate cholesterol homeostasis. Further, the research will be conducted in a leading-edge laboratory, providing students with elite training in a broad range of expertise and techniques in biochemistry, molecular and cell biology.